336 related articles for article (PubMed ID: 27169293)
1. [Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist].
Zheng YC
Yao Xue Xue Bao; 2015 Dec; 50(12):1668-72. PubMed ID: 27169293
[TBL] [Abstract][Full Text] [Related]
2. GLP-1-Exendin-4/IgG4 (Fc) fusion protein as a novel drug for diabetes treatment.
Gan Y; Dang N; Qu Z; Shi R; Ding L; Wang L; Pang S
Exp Clin Endocrinol Diabetes; 2015 Jun; 123(6):371-5. PubMed ID: 25962403
[TBL] [Abstract][Full Text] [Related]
3. Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist.
Wang Q; Chen K; Liu R; Zhao F; Gupta S; Zhang N; Prud'homme GJ
PLoS One; 2010 Sep; 5(9):e12734. PubMed ID: 20856794
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
5. [Expression of human IL-35-IgG4 (Fc) fusion protein in CHO/DG44 cells].
Tang J; Gao W; Zhang Q; Zhang D; Chen Y; He B; Liu Q
Sheng Wu Gong Cheng Xue Bao; 2009 Jan; 25(1):109-15. PubMed ID: 19441235
[TBL] [Abstract][Full Text] [Related]
6. Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2σ-Fc.
Yang Y; Chen F; Wan D; Liu Y; Yang L; Feng H; Cui X; Gao X; Song H
PLoS One; 2016; 11(5):e0156449. PubMed ID: 27232339
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
Nielsen LL; Young AA; Parkes DG
Regul Pept; 2004 Feb; 117(2):77-88. PubMed ID: 14700743
[TBL] [Abstract][Full Text] [Related]
8. Induction of insulin receptor substrate-2 expression by Fc fusion to exendin-4 overexpressed in E. coli: a potential long-acting glucagon-like peptide-1 mimetic.
Kim JW; Kim K; Ahn Y; Jeong H; Jeong H; Ryu S; Lee S; Lee C; Chung HS; Jang SH
BMB Rep; 2010 Feb; 43(2):146-9. PubMed ID: 20193135
[TBL] [Abstract][Full Text] [Related]
9. Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents.
Arakawa M; Ebato C; Mita T; Hirose T; Kawamori R; Fujitani Y; Watada H
Biochem Biophys Res Commun; 2009 Dec; 390(3):809-14. PubMed ID: 19836346
[TBL] [Abstract][Full Text] [Related]
10. The N-terminal alanine-extended GLP-1/IgG-Fc fusion protein confers resistance to DPP-IV and reduces serum glucose level in db/db mice.
Chung HS; Oh JY; Yoo SB; Lee SM; Cho HS
Regul Pept; 2011 Oct; 170(1-3):1-3. PubMed ID: 21621561
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide.
Patterson S; de Kort M; Irwin N; Moffett RC; Dokter WH; Bos ES; Miltenburg AM; Flatt PR
Diabetes Obes Metab; 2015 Aug; 17(8):760-70. PubMed ID: 25929155
[TBL] [Abstract][Full Text] [Related]
12. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein.
Glaesner W; Vick AM; Millican R; Ellis B; Tschang SH; Tian Y; Bokvist K; Brenner M; Koester A; Porksen N; Etgen G; Bumol T
Diabetes Metab Res Rev; 2010 May; 26(4):287-96. PubMed ID: 20503261
[TBL] [Abstract][Full Text] [Related]
13. Effects of GW002, a novel recombinant human glucagon-like peptide-1 (GLP-1) analog fusion protein, on CHO recombinant cells and BKS-db mice.
Ji WW; Yu DA; Fan M; You M; Lu Y; Li EB; Xie N; Yan SS
Acta Diabetol; 2017 Jul; 54(7):685-693. PubMed ID: 28424924
[TBL] [Abstract][Full Text] [Related]
14. Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice.
Gumuslu E; Cine N; Ertan M; Mutlu O; Komsuoglu Celikyurt I; Ulak G
Fundam Clin Pharmacol; 2018 Apr; 32(2):174-180. PubMed ID: 29091313
[TBL] [Abstract][Full Text] [Related]
15. Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice.
Patel V; Joharapurkar A; Dhanesha N; Kshirsagar S; Detroja J; Patel K; Gandhi T; Patel K; Bahekar R; Jain M
Pharmacol Rep; 2013; 65(4):927-36. PubMed ID: 24145087
[TBL] [Abstract][Full Text] [Related]
16. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
17. Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.
Irwin N; Flatt PR; Patterson S; Green BD
Eur J Pharmacol; 2010 Feb; 628(1-3):268-73. PubMed ID: 19917278
[TBL] [Abstract][Full Text] [Related]
18. Biological activity of AC3174, a peptide analog of exendin-4.
Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
[TBL] [Abstract][Full Text] [Related]
19. A Human Glucagon-Like Peptide-1-albumin Recombinant Protein with Prolonged Hypoglycemic Effect Provides Efficient and Beneficial Control of Glucose Metabolism in Diabetic Mice.
Li C; Yang M; Hou G; Liu S; Huan Y; Yu D; Sun S; Liu Q; Yan S; Shen Z
Biol Pharm Bull; 2017 Sep; 40(9):1399-1408. PubMed ID: 28626167
[TBL] [Abstract][Full Text] [Related]
20. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent.
Furman BL
Toxicon; 2012 Mar; 59(4):464-71. PubMed ID: 21194543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
